证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交3.27亿元，其中，买入成交额为2.16亿 元，卖出成交额为1.11亿元，合计净买入1.05亿元。 具体来看，今日上榜的营业部中，沪股通为第二大买入营业部及第二大卖出营业部，买入金额为 5045.15万元，卖出金额为2022.12万元，合计净买入3023.03万元。 资金流向方面，今日该股主力资金净流入2.61亿元，其中，特大单净流入2.44亿元，大单资金净流入 1741.79万元。近5日主力资金净流入2.45亿元。 奥翔药业(603229)今日涨停，全天换手率13.27%，成交额12.53亿元，振幅11.63%。龙虎榜数据显示， 沪股通净买入3023.03万元，营业部席位合计净买入7475.28万元。 上交所公开信息显示，当日该股因日涨幅偏离值达11.22%上榜，沪股通净买入3023.03万元。 融资融券数据显示，该股最新（7月30日）两融余额为3.15亿元，其中，融资余额为3.14亿元，融券余额 为91.26万元。近5日融资余额合计增加4096.09万元，增幅为14.98%。融券余额合计增加41.90万元，增 幅84.88%。 卖五 财通证券股份有限 ...

Summary of Key Points - The company Aoxiang Pharmaceutical (603229.SH) announced that as of July 31, 2025, it has repurchased a total of 1.9994 million shares through centralized bidding, which represents 0.24% of the company's total share capital [1] - The highest price at which the shares were repurchased was 8.57 CNY per share, while the lowest price was 7.52 CNY per share [1] - The total amount paid for the repurchased shares, excluding transaction fees, was 15.5358 million CNY [1]

Group 1 - The company, Aoxiang Pharmaceutical, announced on July 31 that it has repurchased approximately 2 million shares through centralized bidding, accounting for 0.24% of its total share capital, with a total expenditure of about 15.54 million yuan [2] - The highest price for the repurchased shares was 8.57 yuan per share, while the lowest price was 7.52 yuan per share [2] - For the fiscal year 2024, the company's revenue composition is as follows: raw materials and intermediates account for 95.25%, while technical service fees account for 4.75% [2]

证券代码：603229 证券简称：奥翔药业 公告编号：2025-034 浙江奥翔药业股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 浙江奥翔药业股份有限公司(以下简称"公司")股票交易于 2025 年 7 月 29 日、7 月 30 日、7 月 31 日连续三个交易日内收盘价格涨幅偏离值累计超过 20%， 属于股票交易异常波动的情形。 ● 经公司自查并书面问询公司控股股东、实际控制人，截至本公告披露日， 确认不存在应披露而未披露的重大信息。 （一）生产经营情况 经公司自查，公司目前生产经营情况正常，不存在应披露而未披露的重大信 息。 （二）重大事项情况 经公司自查，并向控股股东、实际控制人书面问询确认，截至本公告披露日， 不存在影响公司股票交易异常波动的重大事项，不存在其他应披露而未披露的重 大事项，包括但不限于重大资产重组、股份发行、收购、债务重组、业务重组、 资产剥离和资产注入等重大事项。 （三）媒体报道、市场传闻、热点概念情况 公司未发现对公司股票交易价格可能产生较 ...

证券代码：603229 证券简称：奥翔药业 公告编号：2025-033 格上限由不超过人民币 14 元/股（含）调整为不超过人民币 13.90 元/股（含）。 具体内容详见公司于 2025 年 7 月 10 日披露的《奥翔药业关于 2024 年度权益分派 实施后调整回购价格上限的公告》（公告编号：2025-032）。 二、回购股份的进展情况 浙江奥翔药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/27 | | --- | --- | | 回购方案实施期限 | 2025/1/24~2026/1/23 | | 预计回购金额 | 5,000万元~10,000万元 | | 回购用途 | □减少注册资本 √用于股权激励和/或员工持股计划 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 1,999,400股 | | 累计已回购股数占总股本比例 | 0.24% | | ...

贵公司发来的《浙江奥翔药业股份有限公司关于股票交易 异常波动有关事项的问询函》已收悉。经认真自查核实,现就相 关事项回复如下: 本人作为浙江奥翔药业股份有限公司(以下简称"上市公 司")的控股股东、实际控制人,截至目前,不存在影响上市公 司股票价格异常波动的重大事项,不存在其他应披露而未披露的 重大事项,包括但不限于重大资产重组、发行股份、上市公司收 购、债务重组、业务重组、资产剥离和资产注入等重大事项。 关于《浙江奥翔药业股份有限公司 关于股票交易异常波动有关事项的问询函》的回函 浙江奥翔药业股份有限公司: 特此回复。 控股股东、实际控制人: -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- - 郑志国 2025年 7月3 日 (以下无正文,签署页附后) (本页无正文,为《关于〈浙江奥翔药业股份有限公司关于股票交易 异常波动有关事项的问询函〉的回函》之签署页 ) ...

格隆汇7月31日丨奥翔药业(603229.SH)公布，截至2025年7月31日，公司通过集中竞价交易方式已累计 回购股份199.94万股，已回购股份占公司总股本的比例为0.24%，成交的最高价为8.57元/股、最低价为 7.52元/股，已支付的总金额为1553.58万元（不含交易费用）。 ...

Market Overview - The A-share market experienced a decline with the Shanghai Composite Index falling by 1.18%, the Shenzhen Component Index down by 1.73%, and the ChiNext Index decreasing by 1.66% [1][2] - The total trading volume in the Shanghai and Shenzhen markets reached 1.94 trillion yuan, an increase of 91.7 billion yuan compared to the previous trading day, with over 4,200 stocks declining [1][2] Sector Performance - Sectors such as steel, energy metals, coal mining and processing, photovoltaic equipment, and film and television cinema saw declines, while the liquid cooling server sector showed strong performance [4] - The innovative drug concept continued to perform well, with several stocks including Nanxin Pharmaceutical, Anke Bio, and Aoxiang Pharmaceutical hitting the daily limit [4] - The liquid cooling server concept had multiple stocks, including Yingweike and Icewheel Environment, reaching the daily limit [4][5] Capital Flow - Major funds saw net inflows in sectors like banking, computers, and traditional Chinese medicine, while there were net outflows in mining, paper printing, and electronic components [6] - Specific stocks such as 360, Yidian Tianxia, and Yongyou Network received net inflows of 1.133 billion yuan, 889 million yuan, and 881 million yuan respectively [6] - Conversely, Baogang Group, Dongfang Fortune, and CATL faced net outflows of 1.868 billion yuan, 1.697 billion yuan, and 1.663 billion yuan respectively [6] Institutional Insights - Galaxy Securities suggests not to make bullish moves while the Shanghai Composite Index is below the 5-day moving average, indicating a high probability of filling the gap [6] - Everbright Securities notes that market sentiment remains active, with fluctuations being a normal adjustment within the trend [7] - CITIC Securities maintains that the index is expected to continue its upward trend despite short-term fluctuations [7]

今日奥翔药业（603229）涨10.02%，收盘报10.54元。 2025年4月30日，太平洋研究员周豫,乔露阳发布了对奥翔药业的研报《Q1业绩符合市场预期，持续加大 研发投入》，该研报对奥翔药业给出"买入"评级。研报中预测公司2025/26/27年收入为9.55/11.28/13.93 亿元，净利润为2.80/3.32/4.11亿元，对应当前PE为23/20/16X，考虑到公司原料药及CDMO业务增长稳 定，且制剂业务有望于2025年开始贡献增量收入，持续给予"买入"评级。证券之星数据中心根据近三年 发布的研报数据计算，该研报作者对此股的盈利预测准确度为44.71%。 证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为招商证券的孙炜。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 奥翔药业（603229）个股概况： | 财务摘要 净利润1.19亿元，同比上升5.97%；扣非净利润1.12亿元，同比上升2.81%； | 奥翔药业2025年一季报显示，公司主营收入3.07亿元，同比上升1.9%；归母 | | --- | -- ...

Market Overview - The indices continued to rise collectively, with a significant drop in the morning followed by a recovery in sentiment in the afternoon [3] - The Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index closed up by 0.33%, 0.64%, and 1.86% respectively, with over 3,000 stocks declining and more than 2,200 stocks rising [4] Optimizing Fertility - The "Implementation Plan for Childcare Subsidy System" was officially launched, providing annual subsidies of 3,600 yuan per child for children under three years old starting January 1, 2025 [8] - The fertility optimization sector saw a collective high opening but ended with a "high open low close" trend, with the sector rising by only 0.18% after an initial surge [9][10] - Stocks like Beiyinmei and Aiyingshi opened strongly but fell significantly, while stocks in the dairy sector also experienced a similar pattern [10] Yajiang Hydropower Station - The Yajiang Hydropower Station saw a rebound in the afternoon, with stocks like Xining Special Steel and Tibet Tianlu hitting the daily limit [15] - The Yajiang Hydropower concept stocks rose over 2% by the end of the day, indicating a recovery in investor interest [14] Stablecoin Sector - The stablecoin concept stocks experienced a partial rebound, with companies like Hengbao Co. and Sifang Jichuang showing strong performance [19] - The sector had been quiet for about two weeks but is now looking for a significant catalyst to revive interest [21] Guotou Intelligent - Guotou Intelligent saw a significant rise, closing up over 18.5%, attributed to news regarding a special action by the Internet Information Office [25] - The company is reportedly working on AI fraud prevention services, with a potential market space exceeding 120 billion yuan if it covers 1 billion smartphone users [28]